Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content

Daniela Terracciano, Claudia Mazzarella, Angelina Di Carlo, Angela Mariano, Matteo Ferro, Giuseppe Di Lorenzo, Antonio Giordano, Vincenzo Altieri, Sabino De Placido, Vincenzo Macchia

Research output: Contribution to journalArticlepeer-review

Abstract

Prostate cancer is one of the most frequently diagnosed cancer in men. Treatment by radical prostatectomy, radiotherapy and anti-androgen drugs is successful in patients with localized cancer. However, prolonged androgen deprivation often leads to hormone refractory condition, associated with disease relapse. ErbB1 and ErbB2 activity has been correlated with androgen- independence. We determined the effects of GW2974, a dual inhibitor of ErbB-1 and ErbB-2 tyrosine kinase activity, on growth, NSE, chromogranin A and osteopontin cytosol content in the androgen-independent prostate cancer cell line PC-3. We found that PC-3 cell growth was inhibited by GW2974, whereas NSE and chromogranin A cell contents were stimulated and osteopontin cytosol level was not affected. The present data may have clinical implications for the treatment of advanced prostate cancer.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalOncology Reports
Volume24
Issue number1
DOIs
Publication statusPublished - 2010

Keywords

  • Erbb1
  • Erbb2
  • GW2974
  • NSE
  • PC-3

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content'. Together they form a unique fingerprint.

Cite this